Key Points:
Almost all patients with a BRAFV600E mutation have a Besthesda
diagnostic category of V or VI. Patients with a RAS-type mutation were
categorized as Bethesda III or IV. Preoperative molecular testing of
dominant thyroid nodules may help guide management as patients with
BRAFV600E mutations are likely to have more aggressive disease. Patients
with no molecular mutation identified tended to have less aggressive
thyroid cancer.